Facility Design:A Guide to Maximizing Value

摘要

Rapid growth and changing market dynamics in biologies and vaccine sectors have prompted biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) to build new manufacturing facilities at unprecedented speeds. This often means developing single-use (SU) or hybrid bioprocessing facilities with reusable legacy equipment for production of monoclonal antibodies (MAbs), antibody-drug conjugates (ADCs), and viral-based vectors.